Scholars Central

Conference abstractPublished 2019

Neuroprotective therapy with antioxidative drugs and supplements

Authors: Koji Abe

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Neuroprotection is essential for potential therapy not only in acute stage of stroke but also in chronic progressive neurodegenerative diseases such as ALS, Parkinsonâ??s disease (PD), and Alzheimerâ??s disease (AD). Free radical scavenger can be such a neuroprotective candidate with inhibiting death signals and potentiating survival signals under cerebral ischemia and even neurodegenerative cellular processes. Edaravone is one such free radical scavenger, which is the first clinical drug for neuroprotection in the world and has been used from 2001 in most ischemic stroke patients in Japan. A recent multicenter prospective double-blind placebo-control clinical trial with edaravone for ALS patients conducted in Japan showed a positive effect for delaying the clinical score (ALSFRS-R) during the course of examination (24 weeks). Serious or critical adverse effect was not noted in this clinical trial. Of particular was that this clinical benefit of edaravone was shown as an add-on therapy after anti-glutamatergic riluzole. These data strongly suggest a potential underlying mechanism of oxidative stress in ALS and a clinical delay by a free radical scavenger. Antioxidative supplements are also important choices to prevent or even treat neurological disorders such as ischemic stroke and dementia. Many basic and clinical studies suggest that antioxidative supplements such as Tocovid® (mainly tocotrienol) and TwendeeX® (coenzyme Q+multivitamin) may be effective to ameliorate acute ischemic stroke, chronic cerebral white matter damage, and Alzheimer’s dementia. Recent Publications: 1. Abe K et al., (1988) Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 19: 480-485. 2. Abe K et al., (2017) Safety and efficacy of edaravone in well-defined patients with ALS: a randomized, doubleblind, placebo-controlled trial. Lancet Neurol. 16: 505-512 3. Gopalan Y and Yuen K H (2014) Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. Stroke 45:1422-1428.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Neurology & Neurophysiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Koji Abe”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels